PLBIO(000403) 华鑫证券·2024-11-01 01:13Investment Rating - Buy (Maintained) [2] Core Views - The company's plasma collection and blood product sales continue to grow, with a significant increase in net profit attributable to the parent company of 66% YoY in the first three quarters of 2024 [4] - Operating efficiency has improved, with the net profit margin increasing from 23.70% in the first three quarters of 2023 to 28.71% in the same period of 2024 [5] - The company is actively expanding its overseas market, achieving sales in Pakistan and promoting long-term stable development of overseas business [4] Financial Performance Summary Revenue and Profit - Revenue for the first three quarters of 2024 reached RMB 1.89 billion, a YoY increase of 37.49% [2] - Net profit attributable to the parent company for the first three quarters of 2024 was RMB 543 million, a YoY increase of 66.38% [2] - In the third quarter of 2024, revenue was RMB 754 million, a YoY increase of 13.27%, and net profit attributable to the parent company was RMB 216 million, a YoY increase of 17.86% [3] Operating Efficiency - The company's sales expense ratio, management expense ratio, and R&D expense ratio for the first three quarters of 2024 were 9.98%, 6.93%, and 2.43%, respectively, showing a YoY decrease of 4.73pp, 1.92pp, and 1.48pp [5] Plasma Collection and Sales - The company's plasma collection volume in the first half of 2024 was approximately 700 tons, showing rapid growth [4] - The company continues to deepen its strategic cooperation with Xinjiang Deyuan, extending the cooperation period and increasing plasma supply [4] Overseas Expansion - The company has achieved sales in Pakistan, marking a step forward in its overseas market expansion [4] Financial Forecast - Revenue for 2024-2026 is forecasted to be RMB 2.942 billion, RMB 3.382 billion, and RMB 3.839 billion, respectively [6] - Net profit attributable to the parent company for 2024-2026 is forecasted to be RMB 777 million, RMB 913 million, and RMB 1.067 billion, respectively [6] - EPS for 2024-2026 is forecasted to be RMB 1.06, RMB 1.25, and RMB 1.46, respectively [6] - The current stock price corresponds to a PE ratio of 21.1x, 18.0x, and 15.4x for 2024-2026, respectively [6]